CClinicalTrials.gg
CompletedNCT05512013Updated Nov 29, 2023

The Effects of NSAIDs on Bone Metabolism Following Exercise

A Phase 1 interventional study of Ibuprofen 800 mg and Celecoxib 200mg in Bone Resorption, Stress Fracture and Bone Injury, sponsored by United States Army Research Institute of Environmental Medicine. Completed at 1 site in United States. Open to participants aged 18 Years to 42 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by United States Army Research Institute of Environmental Medicine · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Apr 2023, 3 years 6 months ago, and no results have been posted to the registry.
  • Registered 6 months after the study started (first participant enrolled Feb 2022, registered Aug 2022).
Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 42 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effects of a single dose of non-steroidal anti-inflammatory drugs on post-exercise markers of bone and muscle metabolism.

Read the detailed description

This protocol intends to determine how consuming a single dose of a non-steroidal anti-inflammatory drug (NSAID) affects circulating bone metabolism biomarkers and markers of damage skeletal muscle in response to a bout of plyometric exercise. This will be accomplished using a four trial, placebo-controlled crossover design with trials examining ibuprofen, celecoxib, flurbiprofen and placebo. These particular NSAIDs were chosen because of their widespread use in military populations and differing molecular mechanisms, which could cause differing effects on bone and muscle. Two hours after of consuming a single dose of an NSAID, participants will perform 10 sets of 10 plyometric jumps to induce a mechanical loading stimulus the bone and muscle tissues. Blood, urine, and muscle biopsy samples will be collected before and up to four hours after exercise. Biomarkers representing bone and muscle metabolism will determine the magnitude of adaptive responses to plyometric exercise while using NSAIDs.

02

Conditions studied

  • Bone Resorption
  • Stress Fracture
  • Bone Injury
03

In context

Bone Resorption

153 studies on the registry are indexed under Bone Resorption; 25 are open to participants now.

This study's enrollment of 12 is below the median of 22 across 133 interventional studies indexed under Bone Resorption.

Browse Bone Resorption studies →

Lead sponsor

United States Army Research Institute of Environmental Medicine is the lead sponsor of 67 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 42 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Must currently exercise at least 2 times per week
  • Must be willing to discontinue the use of nutritional supplements, alcohol and nicotine during each study period (4 trials of 5 consecutive days each), unless approved by PI
  • Must be willing to refrain from taking NSAIDs and similar medications during the course of the study (other than those given by the study team)
  • Weigh at least 110 lbs and have a hemoglobin of 12.5 g/dL or higher

Exclusion criteria

Exclusion Criteria:

  • Known allergic reaction to any NSAID type medication
  • History of gastrointestinal disorders/discomfort associated with or which may be aggravated with NSAID use
  • History or known gastric ulcer
  • History of endocrine disorders (e.g., diabetes, uncontrolled thyroid dysfunction, hypoparathyroidism, or hyperparathyroidism)
  • History of bone-modifying disorder (e.g., osteogenesis imperfecta, osteoporosis, or rickets)
  • Diagnosed bone fracture within last 6 months
  • History of cardiovascular or renal diseases
  • Pregnant or lactation in the last 6 months
  • Currently taking or history of routine use of medications known to affect bone or calcium metabolism (e.g., thiazide diuretics, bisphosphonates, oral steroids)
  • History of back or shoulder injury which may be aggravated by exercise
  • Blood donation within 8 weeks of the study
  • Current physical illness or injury limiting physical activity
  • Known allergy to lidocaine
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Ibuprofen

    Participants will consume a single dose of ibuprofen prior to a plyometric exercise bout

    Drug: Ibuprofen 800 mg

  • Experimental
    Celecoxib

    Participants will consume a single dose of celecoxib prior to a plyometric exercise bout

    Drug: Celecoxib 200mg

  • Experimental
    Flurbiprofen

    Participants will consume a single dose of flurbiprofen prior to a plyometric exercise bout

    Drug: Flurbiprofen 100 mg

  • Placebo comparator
    Placebo

    Participants will consume a single dose of an inert placebo prior to a plyometric exercise bout

    Drug: Placebo

Interventions

  • DrugIbuprofen 800 mg

    Ibuprofen taken orally 2 hours prior to exercise

    Also known as: Advil, Motrin

  • DrugCelecoxib 200mg

    Celebrex taken orally 2 hours prior to exercise

    Also known as: Celebrex

  • DrugFlurbiprofen 100 mg

    Flurbiprofen taken orally 2 hours prior to exercise

    Also known as: Ansaid

  • DrugPlacebo

    Inert placebo taken orally 2 hours prior to exercise

06

What researchers measure

Primary outcomes

  1. Change from baseline circulating marker of bone formation

    Concentration (pg/mL) of serum N-terminal propeptide of type 1 collagen (P1NP)

    Time frame: Change from pre-exercise to 4 hours post-exercise

Secondary outcomes

  1. Change from baseline circulating marker of bone resorption

    Concentration (pg/mL) of serum C-terminal propeptide of type I collagen (CTX)

    Time frame: Change from pre-exercise to 4 hours post-exercise

  2. Markers of muscle inflammation

    Interlukin-6 (IL-6), Interlukin-10 (IL-10), and tissue necrosis factor (TNF-a) messenger ribonucleic acid (mRNA) concentration in muscle biopsy tissue

    Time frame: Change from pre-exercise to 3 hours post-exercise

Other outcomes

  1. Muscle protein synthesis

    ribosomal protein S6 (p-RPS6) protein concentration in muscle biopsy tissue

    Time frame: Change from pre-exercise to 3 hours post-exercise

07

Study locations

1 site
  • United States Army Research Institute of Environmental Medicine
    Natick, Massachusetts 01760, United States
08

References and documents

Publications

  • Staab JS, Kolb AL, Tomlinson RE, Pajevic PD, Matheny RW Jr, Hughes JM. Emerging evidence that adaptive bone formation inhibition by non-steroidal anti-inflammatory drugs increases stress fracture risk. Exp Biol Med (Maywood). 2021 May;246(9):1104-1111. doi: 10.1177/1535370221993098. Epub 2021 Feb 27. PubMed 33641442 ↗
  • Jankowski CM, Shea K, Barry DW, Linnebur SA, Wolfe P, Kittelson J, Schwartz RS, Kohrt WM. Timing of Ibuprofen Use and Musculoskeletal Adaptations to Exercise Training in Older Adults. Bone Rep. 2015 Jan 1;1:1-8. doi: 10.1016/j.bonr.2014.10.003. PubMed 25642444 ↗
  • Kohrt WM, Barry DW, Van Pelt RE, Jankowski CM, Wolfe P, Schwartz RS. Timing of ibuprofen use and bone mineral density adaptations to exercise training. J Bone Miner Res. 2010 Jun;25(6):1415-22. doi: 10.1002/jbmr.24. PubMed 20200939 ↗
  • Wherry SJ, Wolfe P, Schwartz RS, Kohrt WM, Jankowski CM. Ibuprofen taken before exercise blunts the IL-6 response in older adults but does not alter bone alkaline phosphatase or c-telopeptide. Eur J Appl Physiol. 2021 Aug;121(8):2187-2192. doi: 10.1007/s00421-021-04691-8. Epub 2021 Apr 19. PubMed 33876259 ↗
  • Brewer CB, Bentley JP, Day LB, Waddell DE. Resistance exercise and naproxen sodium: effects on a stable PGF2alpha metabolite and morphological adaptations of the upper body appendicular skeleton. Inflammopharmacology. 2015 Dec;23(6):319-27. doi: 10.1007/s10787-015-0248-x. Epub 2015 Aug 20. PubMed 26289996 ↗
  • Park J, Fertala A, Tomlinson RE. Naproxen impairs load-induced bone formation, reduces bone toughness, and diminishes woven bone formation following stress fracture in mice. Bone. 2019 Jul;124:22-32. doi: 10.1016/j.bone.2019.04.009. Epub 2019 Apr 15. PubMed 30998998 ↗

Study documents

  • Informed consent form · Jul 27, 2022

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05512013
Lead sponsor
United States Army Research Institute of Environmental Medicine
Responsible party
Jeffery Staab (Principal Investigator, United States Army Research Institute of Environmental Medicine) — Principal investigator
First posted
Aug 23, 2022
Start date
Feb 15, 2022
Primary completion
Apr 1, 2023
Completion
Apr 1, 2023
Last update
Nov 29, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion